Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
The recent outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been characterized by the World Health Organization (WHO) as a controllable global pandemic. The spike (S) glycoprotein mediates binding to the angiotensin-...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-10-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1787064 |
| _version_ | 1797677303439818752 |
|---|---|
| author | Chao Zhang Chenliang Zhou Li Shi Ge Liu |
| author_facet | Chao Zhang Chenliang Zhou Li Shi Ge Liu |
| author_sort | Chao Zhang |
| collection | DOAJ |
| description | The recent outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been characterized by the World Health Organization (WHO) as a controllable global pandemic. The spike (S) glycoprotein mediates binding to the angiotensin-converting enzyme 2 (ACE2) receptor for virus entry and also services as the target of virus-neutralizing antibodies, making it an attractive and leading viral antigen for vaccine development. No vaccine against any human coronavirus is available to date. In learning from the experience of developing Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV vaccine candidates in preclinical and clinical trials, the most promising strategies for SARS-CoV-2 vaccines should employ viral-vector platforms, properly adjuvanted recombinant protein or DNA/mRNA encoding an engineered sequence of trimeric S protein in pre-fusion conformation. |
| first_indexed | 2024-03-11T22:42:45Z |
| format | Article |
| id | doaj.art-cbd1321b8e1a45b89d9cba5a2f858a14 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:45Z |
| publishDate | 2020-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-cbd1321b8e1a45b89d9cba5a2f858a142023-09-22T08:51:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-10-0116102366236910.1080/21645515.2020.17870641787064Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Chao Zhang0Chenliang Zhou1Li Shi2Ge Liu3Shanghai Zerun Biotechnology Co., LtdShanghai Zerun Biotechnology Co., LtdShanghai Zerun Biotechnology Co., LtdShanghai Zerun Biotechnology Co., LtdThe recent outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been characterized by the World Health Organization (WHO) as a controllable global pandemic. The spike (S) glycoprotein mediates binding to the angiotensin-converting enzyme 2 (ACE2) receptor for virus entry and also services as the target of virus-neutralizing antibodies, making it an attractive and leading viral antigen for vaccine development. No vaccine against any human coronavirus is available to date. In learning from the experience of developing Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV vaccine candidates in preclinical and clinical trials, the most promising strategies for SARS-CoV-2 vaccines should employ viral-vector platforms, properly adjuvanted recombinant protein or DNA/mRNA encoding an engineered sequence of trimeric S protein in pre-fusion conformation.http://dx.doi.org/10.1080/21645515.2020.1787064covid-19sars-cov-2vaccine developments protein |
| spellingShingle | Chao Zhang Chenliang Zhou Li Shi Ge Liu Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 vaccine development s protein |
| title | Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| title_full | Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| title_fullStr | Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| title_full_unstemmed | Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| title_short | Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| title_sort | perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 sars cov 2 |
| topic | covid-19 sars-cov-2 vaccine development s protein |
| url | http://dx.doi.org/10.1080/21645515.2020.1787064 |
| work_keys_str_mv | AT chaozhang perspectivesondevelopmentofvaccinesagainstsevereacuterespiratorysyndromecoronavirus2sarscov2 AT chenliangzhou perspectivesondevelopmentofvaccinesagainstsevereacuterespiratorysyndromecoronavirus2sarscov2 AT lishi perspectivesondevelopmentofvaccinesagainstsevereacuterespiratorysyndromecoronavirus2sarscov2 AT geliu perspectivesondevelopmentofvaccinesagainstsevereacuterespiratorysyndromecoronavirus2sarscov2 |